Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Israeli Stocks: Teva, Mellanox, Bio Light and Elbit Imaging

Israel’s TA-25 Index rebounded from the biggest decline in almost three weeks, gaining 2.1 percent to 1,060.29 at the 4:30 p.m. close in Tel Aviv. Investors traded about 783 million shekels ($211 million) of shares and convertible securities today, according to Tel Aviv Stock Exchange data.

The following stocks rose or fell today. Symbols are in parentheses.

Elbit Imaging Ltd. (EMIT IT) climbed 3.4 percent, the most since Sept. 20, to 8.107 shekels. A unit of the investor in real estate and medical companies reached a $30 million loan agreement with Eastgate Property LLC.

Micromedic Technologies Ltd. (MCTC IT) gained 2.9 percent to 2.381 shekels, the highest level since Sept. 6. Bio Light Israeli Life Sciences Investments Ltd. (BOLT IT), a developer of a laser-based technology to treat glaucoma, agreed to buy a controlling stake in the developer of biomedical markers. The shares of Bio Light declined 1.9 percent to 0.212 shekel.

Mellanox Technologies Ltd. (MLNX IT) retreated for a sixth day, declining 2.7 percent to 113.40 shekels, the equivalent of $30.62. The shares of adapter maker that’s part owned by Oracle Corp. narrowed the gap with the U.S.-traded stock, which retreated the most since July 2010 last week to $30.26, after the company announced a share sale.

Teva Pharmaceutical Industries Ltd. (TEVA IT) slumped to the lowest since December 2006, declining 3.1 percent to 130.30 shekels, the equivalent of $35.19. The European Commission extended its review of the world’s largest drugmaker’s planned acquisition of Cephalon Inc. The U.S. traded shares lost 8.6 percent last week to $35.26.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.